1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Opportunity Analyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2024

Opportunity Analyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2024

Summary

Acute myeloid (myelogenous, myelocytic) leukemia (AML) is a rapidly progressing blood cancer with an extremely poor overall prognosis. AML predominantly affects the elderly population and this subgroup of patients has an exceptionally high level of unmet needs. GlobalData estimates the 2014 sales for AML at approximately $342 million across the 7MM covered in this report. The market will increase by almost three-fold over the forecast period, reaching $932 million in 2024 at a CAGR of 10.5%. This growth will be driven by an increase in incident cases of AML as well as the approval and uptake of premium-priced products, such as FLT3 kinase inhibitors (quizartinib and midostaurin), a PI3 kinase inhibitor (volasertib) and new formulations of existing chemotherapies such as Vyxeos (CPX-351), guadecitabine and CC-486. GlobalData expects, by the end of the forecast period, new branded therapies Vyxeos, volasertib and CC-486 will dominate the market along with generic azacitidine. The AML pipeline is weak in terms of efficacy; however, GlobalData expects none of these drugs to have a major impact on the overall AML market. The challenge for new entrants into the AML market is to meet the critically high unmet needs of AML patients and improve overall survival. One of the opportunities for the companies is to work cooperatively to develop therapies that work in combination with chemotherapy backbone.

Highlights

Key Questions Answered

- For over forty years, there has been no major advances in the treatment for AML. The AML space is filled with excitement because the first targeted FLT3 kinase inhibitor therapies are expected to change the treatment landscape. What will be the impact of these newly approved drugs on AML sales?
- With the unmet needs of AML patients remaining critically high, what R&D strategies and opportunities are being used by drug makers to remain competitive?
- The survival of patients with AML remains dismal, especially for those who do not respond to first-line chemotherapies. Therefore, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the AML market?

Key Findings

- One of the main drivers in the expansion of the AML market will be the launch of premium-priced targeted therapies (FLT3 kinase inhibitors, PI3 kinase inhibitor and reformulations of chemotherapy drugs). for patients with extremely high unmet needs, both the elderly and refractory/relapsed population. These drugs will gradually be used in combination with or replace cheaper, generic, cytarabine-based chemotherapy regimens.
- Another driver will be the few players in the AML market, and that current therapies are largely considered to be ineffective. Therefore, there is ample room for new market entrants. A major driver will also be that a growing incident elderly AML population, particularly in the US, will increase the number of treatable AML patients.
- Companies are focusing on the development of combination therapies, trying to improve the complete remission rate and duration of remission.
- One of the largest unmet needs is a need for efficacious treatment options for elderly AML patients. The majority of AML patients do not have FLT3 mutations, and are therefore ineligible for FLT3 inhibitor treatments. Other unmet needs include therapies for refractory/relapsed disease.

Scope

- Overview of AML, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized AML therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in four patient segments (including, young patients, elderly patients, refractory/relapsed patients and FLT3 mutated patients), forecast from 2014 to 2024.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AML therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidate in Phase III development is profiled.
- Analysis of the current and future market competition in the global AML therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global AML therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global melanoma therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table Of Contents

Opportunity Analyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2024
1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 15
1.2 List of Figures 21
2 Introduction 23
2.1 Catalyst 23
2.2 Related Reports 23
2.3 Upcoming Related Reports 23
3 Disease Overview 24
3.1 Etiology and Pathophysiology 24
3.1.1 Pathophysiology 25
3.1.2 Classification 26
3.1.3 Cytogenetic and Molecular Abnormalities 29
3.2 Prognosis 35
3.3 Quality of Life 36
3.4 Symptoms 37
4 Epidemiology 39
4.1 Disease Background 39
4.2 Risk Factors and Comorbidities 40
4.2.1 Increased age is associated with increased risk and worsened prognosis 41
4.2.2 Smoking increases the risk of M2 AML 42
4.2.3 APL is relatively common among Spanish and Italian origins 42
4.2.4 Chemotherapy and radiation therapy increases the risk of AML 43
4.2.5 Benzene increases risk of AML 43
4.3 Global Trends 44
4.3.1 Incidence 44
4.3.2 Survival and Prevalence 46
4.3.3 Subtypes and Mutations 47
4.3.4 Risk Groups 49
4.4 Forecast Methodology 52
4.4.1 Sources Used 53
4.4.2 Forecast Assumptions and Methods 60
4.4.3 Sources not Used 66
4.5 Epidemiological Forecast for Acute Myeloid Leukemia (2014-2024) 67
4.5.1 Adjusted Diagnosed Incident Cases of AML 67
4.5.2 Adjusted Diagnosed Incident Cases of AML by Age 69
4.5.3 Adjusted Diagnosed Incident Cases of AML by Sex 70
4.5.4 Age-Standardized Incidence of AML 72
4.5.5 APL and MDS/tAML 73
4.5.6 APL and MDS/tAML by Age 76
4.5.7 Diagnosed Incident Cases of AML with FLT3 Mutations 78
4.5.8 Diagnosed Incident Cases of AML by Risk Group Classifications 79
4.5.9 Five-Year Diagnosed Prevalent Cases of AML 83
4.5.10 Five-Year Diagnosed Prevalent Cases of AML by Age 84
4.5.11 Five-Year Diagnosed Prevalent Cases of APL and MDS/tAML 85
4.5.12 Five-Year Diagnosed Prevalent Cases of APL and MDS/tAML by Age 87
4.6 Discussion 88
4.6.1 Epidemiological Forecast Insight 88
4.6.2 Limitations of the Analysis 89
4.6.3 Strengths of the Analysis 90
5 Disease Management 91
5.1 Treatment Overview 91
5.2 Response Criteria and Outcome Measures 93
5.3 General Treatment Overview 95
5.3.1 Younger AML Patients 97
5.3.2 Older AML Patients 99
5.4 Hematopoietic Stem Cell Transplant 102
5.5 Monitoring for Residual Disease 104
5.6 Acute Promyelocytic Leukemia 104
6 Current Treatment Options 107
6.1 Overview 107
6.2 Product Profiles - Major Brands 110
6.2.1 Cytarabine 110
6.2.2 Dacogen (decitabine) 114
6.2.3 Vidaza (azacitidine) 120
6.2.4 Mylotarg (gemtuzumab ozogamicin) 128
6.2.5 Other Therapeutic Agents for AML 135
7 Unmet Needs Assessment and Opportunity Analysis 138
7.1 Overview 138
7.2 Unmet Needs Analysis 139
7.2.1 Unmet Need: Therapies that Prolong the OS of AML Patients 139
7.2.2 Unmet Need: Elimination of Residual Disease 142
7.2.3 Unmet Need: Therapies that Achieve Durable CR in AML Patients 142
7.2.4 Unmet Need: Safety 143
7.2.5 Unmet Need: Maintenance Therapies 145
7.2.6 Unmet Need: Improvement in Guidelines Directing the Optimum Course of Therapy 145
7.2.7 Unmet Need: Therapies with More Convenient Administration and Dosing Regimens 146
7.3 Opportunity Analysis 147
7.3.1 Opportunity: Targeting Minimal Residual Disease (Leukemic Stem Cells) 147
7.3.2 Opportunity: Targeting Driver Molecular Mutations with Combination Therapy 147
7.3.3 Opportunity: Development of Immunotherapies for AML 148
7.3.4 Opportunity: Use of Differentiation Agents in AML 149
7.3.5 Opportunity: Development of Oral Maintenance Therapies 149
7.3.6 Opportunity: Development of Safer Conditioning Regimens pre-HSCT 150
8 RandD Strategies 151
8.1 Overview 151
8.1.1 Targeting Multiple Patient Segments 151
8.1.2 Developing Novel Drugs in Combination with Established Therapies 152
8.1.3 Targeting Elderly AML Patients 152
8.1.4 Investigating New Targets Involved in the Pathogenesis of AML 153
8.1.5 Alliances Between Academic Groups and Pharmaceutical Companies 154
8.2 Clinical Trial Design 155
8.2.1 Selection of the Appropriate Efficacy Endpoints to Support Regulatory Approval 155
8.2.2 Selection of Active Comparator 158
8.2.3 Randomization and Stratification of Patients 159
8.2.4 Current Clinical Trial Design 160
8.2.5 Future Trends in Clinical Trial Design 162
9 Pipeline Assessment 164
9.1 Overview 164
9.2 Drugs in Late-Stage Clinical Development 164
9.2.1 CC-486 (oral azacitidine) 166
9.2.2 Guadecitabine (SGI-110) 175
9.2.3 Vyxeos (CPX-351) 184
9.2.4 Qinprezo (vosaroxin) 194
9.2.5 Sapacitabine (CYC682) 201
9.2.6 Gilteritinib (ASP2215) 207
9.2.7 Midostaurin (PKC412) 213
9.2.8 Quizartinib (AC220) 221
9.2.9 Volasertib (BI 6727) 229
9.2.10 Ganetespib (STA-9090) 236
9.3 Innovative Early-Stage Approaches 241
9.3.1 Biologic-Targeted Therapies 242
9.3.2 Immunotherapies 246
9.3.3 Epigenetic Approaches 249
9.3.4 Stem Cell Therapies and other Cell-Based Regimens 254
10 Pipeline Valuation Analysis 255
10.1 Clinical Benchmark of Key Pipeline Drugs 256
10.2 Commercial Benchmark of Key Pipeline Drugs 260
10.3 Competitive Assessment 263
10.4 Top-Line -Year Forecast 264
10.4.1 US 268
10.4.2 5EU 270
10.4.3 Japan 272
11 Appendix 274
11.1 Bibliography 274
11.2 Abbreviations 299
11.3 Methodology 306
11.4 Forecasting Methodology 306
11.4.1 Diagnosed AML Patients 306
11.4.2 Percent Drug-treated Patients 307
11.4.3 Drugs Included in Each Therapeutic Class 307
11.4.4 Launch and Patent Expiry Dates 308
11.4.5 General Pricing Assumptions 308
11.4.6 General Forecast Assumptions 310
11.4.7 Individual Drug Assumptions 312
11.4.8 Generic Erosion 319
11.4.9 Pricing of Pipeline Agents 319
11.5 Physicians and Specialists Included in this Study 321
11.5.1 Primary Research - Prescriber Survey 322
11.6 About the Authors 323
11.6.1 Authors 323
11.6.2 Epidemiologist 324
11.6.3 Global Head of Healthcare 324
11.7 About GlobalData 325
11.8 Disclaimer 325

1.1 List of Tables
Table 1: Classification of AML Subtypes - WHO System 28
Table 2: Classification of AML Subtypes - FAB System 29
Table 3: Common Cytogenetic Abnormalities in AML 31
Table 4: Symptoms of AML 38
Table 5: Risk Factors for AML in Adults 41
Table 6: Incidence of AML per 100,000 Population in Japan, 1993-2002, All Ages 46
Table 7: Estimated Frequencies of Cytogenetic Abnormalities in AML 50
Table 8: Risk Group Classification Guidelines 51
Table 9: 7MM, Sources of AML Diagnosed Incidence 53
Table 10: 7MM, Adjusted Diagnosed Incident Cases of AML, Both Sexes, Ages ?20 Years, N, Selected Years, 2014-2024 68
Table 11: 7MM, Adjusted Diagnosed Incident Cases of AML by Age, Both Sexes, N (Row %), 2014 69
Table 12: 7MM, Adjusted Diagnosed Incident Cases of AML by Sex, N (Row %), 2014 71
Table 13: 7MM, Diagnosed Incident Cases of APL, Both Sexes, Ages ?20 Years, N, Selected Years, 2014-2024 74
Table 14: 7MM, Diagnosed Incident Cases of MDS/tAML, Both Sexes, Ages ?20 Years, N, Selected Years, 2014-2024 75
Table 15: 7MM, Diagnosed Incident Cases of AML Subtypes by Age, Both Sexes, N (Row % in Each Subtype), 2014 77
Table 16: 7MM, Diagnosed Incident Cases of AML with FLT3 Mutations, Both Sexes, Ages ?20 Years, N, Selected Years 2014-2024 79
Table 17: 7MM, Diagnosed Incident Cases of AML by Risk Group Classification, Both Sexes, Ages ?20 Years, N (Row %), 2014 80
Table 18: US, Risk Group Classification of AML Incident Cases by Age, Both Sexes, N (Row %), 2014 82
Table 19: 7MM, Five-Year Diagnosed Prevalent Cases of AML, Both Sexes, Ages ?20 Years, N, Selected Years, 2014-2024 83
Table 20: 7MM, Five-Year Diagnosed Prevalent Cases of AML by Age, Both Sexes, N (Row %), 2014 85
Table 21: 7MM, Five-Year Diagnosed Prevalent Cases of APL, Both Sexes, Ages ?20 Years, N, Selected Years, 2014-2024 86
Table 22: 7MM, Five-Year Diagnosed Prevalent Cases of MDS/tAML, Both Sexes, Ages ?20 Years, N, Selected Years, 2014-2024 87
Table 23: 7MM, Five-Year Diagnosed Prevalent Cases of AML Subtypes by Age, Both Sexes, N (Row %), 2014 88
Table 24: Types of Responses - AML 94
Table 25: Outcome Measures in AML 94
Table 26: Induction and Consolidation Regimens for APL by Patient Risk Group 106
Table 27: Leading Treatments for AML 109
Table 28: Product Profile - Cytarabine (generic) 112
Table 29: Cytarabine SWOT Analysis 114
Table 30: Product Profile - Dacogen 115
Table 31: Efficacy of Dacogen vs Physicians' Choice of Treatment (DACO-016 Trial; NCT00260832) 118
Table 32: Safety of Dacogen (decitabine) in AML Patients (DACO-016 Trial; NCT00260832) 119
Table 33: Dacogen SWOT Analysis 120
Table 34: Product Profile - Vidaza 122
Table 35: Efficacy of Vidaza vs Conventional Care Regimens in Newly Diagnosed or Secondary Elderly AML Patients with >30% Blasts (NCT01074047; AML-001) 125
Table 36: Safety of Vidaza (azacitidine) in Newly Diagnosed or Secondary Elderly AML Patients with >30% Blasts (NCT01074047; AML-001) 126
Table 37: Vidaza SWOT Analysis 127
Table 38: Product Profile - Mylotarg (Gemtuzumab Ozogamicin [GO]) 131
Table 39: Efficacy of Mylotarg vs Best Supportive Care in Previously Untreated Elderly AML Patients (NCT00091234; AML-19) 133
Table 40: Safety of Mylotarg in Previously Untreated Elderly AML Patients (NCT00091234; AML-19) 134
Table 41: Mylotarg SWOT Analysis 135
Table 42: Other Therapeutic Agents Prescribed for AML 137
Table 43: Overall Unmet Needs in AML - Current Level of Attainment 139
Table 44: Design of Current Phase III Trials in AML 160
Table 45: AML - Late-Stage Pipeline, 2015 166
Table 46: Product Profile - CC-486 168
Table 47: Efficacy of CC-486 in AML Patients 171
Table 48: Efficacy of CC-486 Extended Dosing Schedules in WHO-defined RAEB-1 or RAEB-2 MDS (Ad-hoc analysis of two ongoing Phase I/II studies) 172
Table 49: Safety of CC-486 in AML Patients 173
Table 50: CC-486 SWOT Analysis 174
Table 51: Global Sales Forecast ($m) for CC-486, 2014-2024 175
Table 52: Product Profile - Guadecitabine 176
Table 53: Efficacy of Guadecitabine in Previously Untreated Elderly AML Patients (Trial NCT02348489) 178
Table 54: Efficacy of Guadecitabine in Elderly Patients Ineligible for Intensive Chemotherapy (Trial NCT01261312) 179
Table 55: Safety of Guadecitabine in Elderly Patients Ineligible for Intensive Chemotherapy 180
Table 56: Safety of Guadecitabine in Previously Untreated Elderly AML Patients (Trial NCT02348489) 181
Table 57: Safety of Guadecitabine in Refractory/Relapsed AML Patients 182
Table 58: Guadecitabine SWOT Analysis 182
Table 59: Global Sales Forecast ($m) for Guadecitabine (SGI-110), 2014-2024 183
Table 60: Product Profile - Vyxeos 185
Table 61: Efficacy of Vyxeos versus 7+3 Regimen in Patients Between 60 and 75 Years of Age with Newly Diagnosed AML (Trial NCT00788892) 189
Table 62: Efficacy of Vyxeos in AML Patients (18-65 years of age) in First Relapse (Trial NCT00822094) 190
Table 63: Safety of Vyxeos in AML Patients (18-65 years of age) in First Relapse (Trial NCT00822094) 192
Table 64: Vyxeos SWOT Analysis 193
Table 65: Global Sales Forecast ($m) for Vyxeos, 2014-2024 194
Table 66: Product Profile - Qinprezo 196
Table 67: Efficacy of Qinprezo in Refractory/Relapsed AML Patients of All Ages (Trial NCT01191801; VALOR) 198
Table 68: Safety of Qinprezo in Refractory/Relapsed AML Patients of All Ages (Trial NCT01191801; VALOR) 199
Table 69: Qinprezo SWOT Analysis 200
Table 70: Global Sales Forecast ($m) for Qinprezo, 2014-2024 201
Table 71: Product Profile - Sapacitabine 202
Table 72: Efficacy of Sapacitabine in Elderly Patients with Newly Diagnosed AML (>70 years) (Trial NCT01303796; SEAMLESS) 204
Table 73: Safety of Sapacitabine in Elderly Patients with Newly Diagnosed AML (Trial NCT01303796) 205
Table 74: Sapacitabine SWOT Analysis 206
Table 75: Global Sales Forecast ($m) for Sapacitabine, 2014-2024 207
Table 76: Product Profile - Gilteritinib 208
Table 77: Efficacy of Gilteritinib in Refractory/Relapsed AML Patients (Trial NCT02014558) 210
Table 78: Safety of Gilteritinib in Refractory/Relapsed AML Patients (Trial NCT02014558) 211
Table 79: Gilteritinib SWOT Analysis 212
Table 80: Global Sales Forecast ($m) for Gilteritinib, 2014-2024 213
Table 81: Product Profile - Midostaurin 214
Table 82: Efficacy of Midostaurin in Combination with Vidaza in Patients with AML/MDS (>65 years of age) (Trial NCT01202877) 217
Table 83: Safety of Midostaurin in Combination with Vidaza in Patients with AML/MDS (>65 years of age) (NCT01202877) 219
Table 84: Midostaurin SWOT Analysis 220
Table 85: Global Sales Forecast ($m) for Midostaurin, 2014-2024 221
Table 86: Product Profile - Quizartinib 222
Table 87: Efficacy of Quizartinib in FLT3-ITD(+) Refractory/Relapsed AML Patients (Trial NCT01565668) 225
Table 88: Efficacy of Quizartinib in FLT3-ITD(+) Refractory/Relapsed AML Patients as a Bridge to HSCT 226
Table 89: Safety of Quizartinib in FLT3-ITD(+) Refractory/Relapsed AML Patients (Trial NCT01565668) 226
Table 90: Quizartinib SWOT Analysis 228
Table 91: Global Sales Forecast ($m) for Quizartinib, 2014-2024 229
Table 92: Product Profile - Volasertib 230
Table 93: Efficacy of Volasertib with LDAC in Elderly AML Patients Ineligible for Intensive therapy (Trial NCT00804856) 233
Table 94: Safety of Volasertib with LDAC in Elderly AML Patients Ineligible for Intensive Therapy (Trial NCT00804856) 234
Table 95: Volasertib SWOT Analysis 235
Table 96: Global Sales Forecast ($m) for Volasertib, 2014-2024 236
Table 97: Product Profile - Ganetespib 237
Table 98: Ganetespib SWOT Analysis 240
Table 99: Global Sales Forecast ($m) for Ganetespib, 2014-2024 241
Table 100: Early-Stage Pipeline Products in AML 242
Table 101: Clinical Benchmark of Key Pipeline Drugs - First-Line Therapies for Newly Diagnosed AML Patients (all ages >20 years) 256
Table 102: Clinical Benchmark of Key Pipeline Drugs - First-Line Therapies for Newly Diagnosed AML Patients (all ages >20 years) 257
Table 103: Clinical Benchmark of Key Pipeline Drugs - Refractory/Relapsed AML Patients (all ages >20 years) 258
Table 104: Commercial Benchmark of Key Marketed and Pipeline Drugs - First-Line Therapies for Newly Diagnosed AML patients (all ages >20 years) 260
Table 105: Commercial Benchmark of Key Pipeline Drugs - First-Line Therapies for Newly Diagnosed AML Patients (all ages >20 years) 261
Table 106: Commercial Benchmark of Key Pipeline Drugs - Relapsed/Refractory AML Patients (all ages >20 years) 262
Table 107: Global Top-Line Sales Forecasts ($m) for AML, 2014-2024 265
Table 108: Key Events Impacting Sales for AML in the US, 2014-2024 267
Table 109: Key Events Impacting Sales for AML in Japan, 2014-2024 268
Table 110: Key Events Impacting Sales for AML in the 5EU, 2014-2024 268
Table 111: AML Market in the US - Drivers and Barriers, 2014 270
Table 112: 5EU AML Market - Drivers and Barriers, 2014 272
Table 113: Japan AML Market - Drivers and Barriers, 2014 273
Table 114: Key Launch Dates 308
Table 115: Key Patent Expiries 308
Table 116: Average Body Weight, Height and Surface Area, Across the 7MM 309
Table 117: High-Prescribing Physicians Surveyed by Country 322

1.2 List of Figures
Figure 1: Comparison of Normal and Leukemia Blood Cell Differentiation 26
Figure 2: 7MM, Adjusted Diagnosed Incident Cases of AML, Both Sexes, Ages ?20 Years, N, 2014-2024 68
Figure 3: 7MM, Adjusted Diagnosed Incident Cases of AML by Age, Both Sexes, Ages ?20 Years, N, 2014 70
Figure 4: 7MM, Adjusted Diagnosed Incident Cases of AML by Sex, Ages ?20 Years, N, 2014 72
Figure 5: 7MM, Age-Standardized Adjusted Diagnosed Incidence of AML, Ages ?20 Years, 2014 73
Figure 6: 7MM, Diagnosed Incident Cases of APL, and MDS/tAML, Both Sexes, Ages ?20 Years, N, 2014 and 2024 76
Figure 7: 7MM, Diagnosed Incident Cases of AML Subtypes by Age, Both Sexes, N, 2014 78
Figure 8: 7MM, Diagnosed Incident Cases of AML by Risk Group Classification, Both Sexes, Ages ?20 Years, N, 2014 81
Figure 9: US, Risk Group Classification of AML Incident Cases by Age, Both Sexes, N, 2014 82
Figure 10: 7MM, Five-Year Diagnosed Prevalent Cases of AML, Both Sexes, Ages ?20 Years, N, 2014-2024 84
Figure 11: Dacogen's Development in AML 117
Figure 12: Vidaza's Development in AML 124
Figure 13: Mylotarg's Development in AML 131
Figure 14: CC-486's Development in AML 170
Figure 15: Guadecitabine's (SGI-110) Development in AML 177
Figure 16: Vyxeos' Development in AML 188
Figure 17: Qinprezo's (vosaroxin) Development in AML 197
Figure 18: Sapacitabine's Development in AML 203
Figure 19: Gilteritinib's (ASP2215) Development in AML 209
Figure 20: Midostaurin's (PKC412) Development in AML 216
Figure 21: Quizartinib's Development in AML 224
Figure 22: Volasertib's Development in AML 231
Figure 23: Ganetespib's Development in AML 238
Figure 24: Competitive Assessment of Late-Stage Pipeline Agents in AML, 2014-2024 264
Figure 25: Global Sales for AML by Region, 2014-2024 266

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.